Schering-Plough Gets FDA Panel Support for Nonprescription Claritin
The drug company said an FDA panel supports making the popular allergy medicine nonprescription.
Schering-Plough
(SGP)
was up in premarket trading on news that a Food and Drug Administration advisory committee had recommended approval for Claritin as a nonprescription treatment for chronic hives.
The Nonprescription Drugs Advisory Committee said it supports the over-the-counter use of three formulations of Claritin - tablets, reditabs, and syrup - in the treatment of chronic idiopathic urticaria, or hives. Schering-Plough has announced plans to seek approval for all versions of Claritin as a nonprescription treatment for seasonal allergies and hives.
Shares of SGP were recently up 4% to $30.90 in premarket trading on the Instinet platform after closing at $29.70 Monday.
